123 related articles for article (PubMed ID: 33148491)
1. In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition.
Bazin MA; Cojean S; Pagniez F; Bernadat G; Cavé C; Ourliac-Garnier I; Nourrisson MR; Morgado C; Picot C; Leclercq O; Baratte B; Robert T; Späth GF; Rachidi N; Bach S; Loiseau PM; Le Pape P; Marchand P
Eur J Med Chem; 2021 Jan; 210():112956. PubMed ID: 33148491
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, antileishmanial activity and cytotoxicity of 2,3-diaryl- and 2,3,8-trisubstituted imidazo[1,2-a]pyrazines.
Marchand P; Bazin MA; Pagniez F; Rivière G; Bodero L; Marhadour S; Nourrisson MR; Picot C; Ruchaud S; Bach S; Baratte B; Sauvain M; Pareja DC; Vaisberg AJ; Le Pape P
Eur J Med Chem; 2015 Oct; 103():381-95. PubMed ID: 26383125
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection.
Rachidi N; Taly JF; Durieu E; Leclercq O; Aulner N; Prina E; Pescher P; Notredame C; Meijer L; Späth GF
Antimicrob Agents Chemother; 2014; 58(3):1501-15. PubMed ID: 24366737
[TBL] [Abstract][Full Text] [Related]
4. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of casein kinase 1 block the growth of Leishmania major promastigotes in vitro.
Allocco JJ; Donald R; Zhong T; Lee A; Tang YS; Hendrickson RC; Liberator P; Nare B
Int J Parasitol; 2006 Oct; 36(12):1249-59. PubMed ID: 16890941
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents.
Marhadour S; Marchand P; Pagniez F; Bazin MA; Picot C; Lozach O; Ruchaud S; Antoine M; Meijer L; Rachidi N; Le Pape P
Eur J Med Chem; 2012 Dec; 58():543-56. PubMed ID: 23164660
[TBL] [Abstract][Full Text] [Related]
7. Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB; Williams MJ; Curran PJ; Mandal AK; Meng Z; Rainka MP; Yu T; Shih NY; Siddiqui MA; Liu M; Tevar S; Lee S; Liang L; Gray K; Yaremko B; Jones J; Smith EB; Prelusky DB; Basso AD
Bioorg Med Chem Lett; 2010 Nov; 20(22):6739-43. PubMed ID: 20855207
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ
Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569
[TBL] [Abstract][Full Text] [Related]
9. Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
Robarge KD; Lee W; Eigenbrot C; Ultsch M; Wiesmann C; Heald R; Price S; Hewitt J; Jackson P; Savy P; Burton B; Choo EF; Pang J; Boggs J; Yang A; Yang X; Baumgardner M
Bioorg Med Chem Lett; 2014 Oct; 24(19):4714-4723. PubMed ID: 25193232
[TBL] [Abstract][Full Text] [Related]
10. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
[TBL] [Abstract][Full Text] [Related]
11. Achieving effective and selective CK1 inhibitors through structure modification.
Du C; Yang H; Feng F; Liu W; Chen Y; Sun H
Future Med Chem; 2021 Mar; 13(5):505-528. PubMed ID: 33438471
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775
[TBL] [Abstract][Full Text] [Related]
13. Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.
Mitchell SA; Danca MD; Blomgren PA; Darrow JW; Currie KS; Kropf JE; Lee SH; Gallion SL; Xiong JM; Pippin DA; DeSimone RW; Brittelli DR; Eustice DC; Bourret A; Hill-Drzewi M; Maciejewski PM; Elkin LL
Bioorg Med Chem Lett; 2009 Dec; 19(24):6991-5. PubMed ID: 19879134
[TBL] [Abstract][Full Text] [Related]
14. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
[TBL] [Abstract][Full Text] [Related]
15. Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors.
Patinote C; Bou Karroum N; Moarbess G; Deleuze-Masquefa C; Hadj-Kaddour K; Cuq P; Diab-Assaf M; Kassab I; Bonnet PA
Eur J Med Chem; 2017 Sep; 138():909-919. PubMed ID: 28750313
[TBL] [Abstract][Full Text] [Related]
16. Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors.
Meng Z; Kulkarni BA; Kerekes AD; Mandal AK; Esposite SJ; Belanger DB; Reddy PA; Basso AD; Tevar S; Gray K; Jones J; Smith EB; Doll RJ; Siddiqui MA
Bioorg Med Chem Lett; 2011 Jan; 21(1):592-8. PubMed ID: 21075632
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 2-(1H-imidazo-2-yl)piperazines as a new class of potent and non-cytotoxic inhibitors of Trypanosoma brucei growth in vitro.
Ferrigno F; Biancofiore I; Malancona S; Ponzi S; Paonessa G; Graziani R; Bresciani A; Gennari N; Di Marco A; Kaiser M; Summa V; Harper S; Ontoria JM
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3689-3692. PubMed ID: 30482621
[TBL] [Abstract][Full Text] [Related]
18. 2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors.
Hua Z; Huang X; Bregman H; Chakka N; DiMauro EF; Doherty EM; Goldstein J; Gunaydin H; Huang H; Mercede S; Newcomb J; Patel VF; Turci SM; Yan J; Wilson C; Martin MW
Bioorg Med Chem Lett; 2012 Sep; 22(17):5392-5. PubMed ID: 22877629
[TBL] [Abstract][Full Text] [Related]
19. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Biological Activity, and Mechanism of Action of 2-Pyrazyl and Pyridylhydrazone Derivatives, New Classes of Antileishmanial Agents.
Coimbra ES; Antinarelli LMR; de A Crispi M; Nogueira TCM; Pinheiro AC; de Souza MVN
ChemMedChem; 2018 Jul; 13(14):1387-1394. PubMed ID: 29790287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
